On Tuesday, Following Stocks were among the “Top Gainers” of U.S. Stock Market: Sequenom, (NASDAQ:SQNM), BioCryst Pharmaceuticals, (NASDAQ:BCRX), Idera Pharmaceuticals, (NASDAQ:IDRA), Companhia de Saneamento, (NYSE:SBS)
Sequenom, (NASDAQ:SQNM), with shares gained 1.02%, closed at $3.95.
BioCryst Pharmaceuticals, (NASDAQ:BCRX), with shares jumped 5.37%, settled at $9.03.
Idera Pharmaceuticals, (NASDAQ:IDRA), with shares climbed 3.92%, and closed at $3.71.
Companhia de Saneamento, (NYSE:SBS), surged 5.24%, and closed at $5.42.
Latest NEWS regarding these Stocks are depicted underneath:
Sequenom Inc. (NASDAQ:SQNM)
Sequenom Inc. (SQNM), presented six scientific posters on noninvasive prenatal testing (NIPT) and supported a ongoing medical education (CME) satellite symposium through an unrestricted educational grant at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting, which was held on March 24-28, 2015 in Salt Lake City, Utah.
Sequenom, Inc., a life sciences corporation, develops and commercializes molecular diagnostics testing services for the women’s health and oncology markets in the United States and internationally.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc. (BCRX), declared that the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded BioCryst a contract for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, counting filoviruses. This ASPR/BARDA contract comprises a base contract of $12.1 million to support BCX4430 drug manufacturing, in addition to $22.9 million in additional development options that can be exercised by the Government, bringing the potential value of the contract to $35.0 million. Filoviruses represent serious threats to national security and the U.S. Government has made this a top priority for medical countermeasure development.
The scope of work under the base contract mainly focuses on drug manufacturing, counting process improvement, scale up and manufacture of BCX4430 in the U.S over an 18 month period. The BCX4430 produced under this contract is predictable to be used in clinical studies and non-clinical toxicology studies supporting the filing of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for both intravenous (i.v.) and intramuscular (i.m.) formulations of BCX4430.
BioCryst Pharmaceuticals, Inc., a biotechnology corporation, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its product candidates comprise peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza; BCX4161, an oral serine protease inhibitor, which is in Phase II clinical trial for hereditary angioedema (HAE); and BCX7353 and other second generation HAE compounds, which are oral serine protease inhibitors that are in preclinical trial for HAE.
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
Formerly on March 12, Idera Pharmaceuticals, Inc. (IDRA), stated Net loss applicable to ordinary stockholders for the three months ended December 31, 2014 was $12.0 million, or $0.14 per diluted share, contrast to a net loss applicable to ordinary stockholders of $6.4 million, or $0.10 per diluted share, for the same period in 2013. There was nominal proceed recognized in each of the fourth quarters of 2014 and 2013. Research and development expenses for the three months ended December 31, 2014 totaled $8.2 million contrast to $3.6 million for the same period in 2013. General and administrative expense for the three months ended December 31, 2014 totaled $3.7 contrast to $2.4 million for the same period in 2013.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical corporation, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States.
Companhia de Saneamento Basico do Estado de Sao Paulo (NYSE:SBS)
Companhia de Saneamento Basico do Estado de Sao Paulo (SBS), following CVM Instruction 358 of January 3, 2002, and amendments thereto, hereby informs its shareholders and the market in general that, on March 31, 2015, the Sao Paulo State Sanitation and Energy Regulatory Agency (ARSESP) published a notice on the Official Gazette of the State of Sao Paulo (DOE), announcing that it is submitting for Public Consultation a proposal for Sabesp’s Extraordinary Tariff Revision, according to Preliminary Technical Note RTS/003/2015, which implies in a total tariff adjustment of 13.97%, 7.06% of which refers to tariff adjustment by the IPCA (Amplified Consumer Price Index) minus the efficiency factor; and 6.36% refers to the extraordinary revision.
At the same time, ARSESP informed that the Public Consultation period will end on April 15.
Companhia de Saneamento Básico do Estado de São Paulo SABESP provides basic and environmental sanitation services; and supplies treated water on a wholesale basis to residential, commercial, industrial, and governmental customers in the state of São Paulo. Its activities comprise water supply; sanitary sewage services; urban rainwater administration and drainage services; urban cleaning services; solid waste administration services; and related activities, counting the planning, operation, maintenance, and commercialization of energy.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
